Selecta Biosciences ImmTOR - Immune Tolerance Platform
Selecta Biosciences’ immune tolerance platform, ImmTOR, is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses.
Selecta Biosciences’ immune tolerance platform, ImmTOR, is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses.
ImmTOR has the potential to unlock the full potential of biologic therapies, including enabling redosing of life saving gene therapies, and to restore self-tolerance in autoimmune diseases.
The universal formulation of ImmTORTM is produced at a commercial scale via a well-controlled and scalable manufacturing process.
Selecta has developed a commercial-scale, Good Manufacturing Practice (GMP), process to ensure that ImmTOR is consistently produced and controlled according to quality standards.
ImmTOR’s tolerogenic activity has been reproduced in multiple independent laboratories using a range of biologic therapies and immunogenic antigens, validating the platform’s ability to mitigate anti-drug antibodies. This research has been published in several high-level peer-reviewed journals including Nature Nanotechnology, Nature Communications and Proceedings of the National Academy of Sciences of the United States of America (PNAS).